Status: Recruiting
A Dose Escalation and Expansion Study of GIGA-564 in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
The purpose of this study is to assess the safety and tolerability of GIGA-564 and identify the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) level(s) of GIGA-564 in participants with metastatic or locally advanced solid tumor malignancies.
Participants needed: 60
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: GigaGen, Inc.Updated: Apr 10, 2025Locations: 1
Eligibility criteria
Willing and able to provide informed consent. [+14]
Investigational therapy and/or anti-cancer therapy with the potential for late o... [+19]